摘要
Fanconi贫血(FA)是常染色体隐性,多系统DNA修复紊乱在造血干细胞维护的突出缺点导致了在学龄前期逐步磨损和失败。已证明同种异体干细胞移植对于具有合适供体的患者是有效的。这连同相对于非校正的FA干细胞的表型正常的特征生存优势强调了干细胞基因治疗在FA中的令人信服的理由。尽管整合慢病毒载体(LV)已成为在几种血液学和免疫缺陷病症中用于遗传校正的优选平台,但是这些载体的残余致癌潜力引起了关于插入突变遗传损伤的FA干细胞的关注。在这种背景下,研究者正在开发新一代非整合型病毒载体,其能够通过连续有丝分裂周期的核持续,并在选择下稳定以抵消相对较低的转导率。在这里,我们审查了竞争的方法来开发这样的非整合慢病毒(NILV)附加体载体忠实地在干细胞中复制。
关键词: Fanconi贫血,造血干/祖细胞,基因治疗,病毒载体,S / MAR。
Current Gene Therapy
Title:Anchored Lentiviral Vector Episomes for Stem Cell Gene Therapy in Fanconi Anemia
Volume: 16 Issue: 5
关键词: Fanconi贫血,造血干/祖细胞,基因治疗,病毒载体,S / MAR。
摘要: Fanconi anemia (FA) is an autosomal recessive, multisystem DNA repair disorder with prominent defects in the hematopoietic stem cell maintenance that result in the progressive attrition and failure in the early school age. Allogeneic stem cell transplantation has proved curative for patients with suitable donors. This, along with the characteristic survival advantage of phenotypically normal over non-corrected FA stem cells underscores the compelling rationale for stem cell gene therapy in the FA. While integrating lentiviral vectors (LV) have become the preferred platform for genetic correction in several hematologic and immunodeficiency disorders, the residual oncogenic potential by these vectors raises concerns in the FA stem cells about insertional mutagenic genetic lesions. On this backdrop, investigators are developing a new generation of non-integrating viral vectors capable of nuclear persistence through serial mitotic cycles and stable under selection to offset the comparatively lower transduction rates. Here, we review the competing approaches to develop such non-integrating lentiviral (NILV) episome vectors that faithfully replicate in the stem cells.
Export Options
About this article
Cite this article as:
Anchored Lentiviral Vector Episomes for Stem Cell Gene Therapy in Fanconi Anemia, Current Gene Therapy 2016; 16 (5) . https://dx.doi.org/10.2174/1566523217666170113165407
DOI https://dx.doi.org/10.2174/1566523217666170113165407 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements